OIA response: Special Authority funding data for lenalidomide (Revlimid)

1 October 2020

Dear [name and contact details redacted]

REQUEST FOR INFORMATION

Thank you for your request dated 10 September 2020 under the Official Information Act 1982 (OIA) for information relating to Special Authority (SA) data for lenalidomide (Revlimid) maintenance. You asked for:

  • any numbers on the uptake of lenalidomide for the newly subsidised maintenance indication

Please refer to the table below for the number of approved applications under the new indication ‘maintenance following first-line autologous stem cell transplant (SCT)’ submitted since 1 April 2020 (effective date of new SA indication).

Financial Year

Month Submitted

Initial application

Renewal

2020

2020-04-01

44

1

 

2020-05-01

21

2

 

2020-06-01

11

0

2021

2020-07-01

4

4

 

2020-08-01

3

2

We trust that this information answers your queries. We are making our information more freely available, so we will now publish selected OIA responses (excluding personal details) on our website.  Please get in touch with us if you have any questions about this.

Yours sincerely 

Rachel Read
Manager, Policy and Government Services